Okogen Acquires Ranpirnase Assets, Expanding Antiviral Pipeline Across Multiple Therapeutic Areas

Okogen Inc., a biotechnology company developing antiviral therapeutics, announced the acquisition of the global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc. (NASDAQ: ORGS). This strategic move strengthens the company's lead ophthalmic program while establishing a foundation for expansion into additional antiviral indications. The acquisition expands Okogen's development pipeline beyond ocular infections into focused therapeutic areas including eyecare, systemic infectious disease, dermatology, and medical countermeasures for high-consequence pathogens such as filoviruses. These areas form the core pillars of what the company now calls its Ranpirnase Platform.

The company prioritizes rapid advancement of its lead ranpirnase program, OKG-0303, an investigational therapy for acute infectious conjunctivitis. This disease area currently suffers from fragmented treatment approaches with no single therapy addressing both viral and bacterial causes. The acquisition provides Okogen with full control over ranpirnase development, which has been evaluated in clinical trials involving more than 1,000 patients, generating substantial safety and translational data supporting continued development. Ranpirnase represents a differentiated approach to antiviral development through its host-directed mechanism that disrupts viral replication inside infected cells by degrading intracellular RNA involved in protein synthesis. This creates a translational bottleneck that limits production of viral proteins required for replication, potentially reducing susceptibility to resistance observed with traditional direct-acting antivirals as detailed in research available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077210/.

Beyond ophthalmology, Okogen advances ranpirnase as a potential antiviral medical countermeasure and engages with U.S. and international government agencies to evaluate its role against high-consequence pathogens such as Marburg and Sudan viruses. The company simultaneously progresses parallel research in respiratory viruses including influenza and RSV. This expansion into multiple therapeutic areas represents a significant strategic shift for Okogen, transforming the company from a focused ocular therapeutics developer into a broader antiviral platform company. The ranpirnase acquisition provides the company with a validated molecule that has demonstrated safety in human trials while offering a novel mechanism of action that could address multiple viral threats across different organ systems. The importance of developing effective antiviral treatments for ocular infections is well-documented in medical literature, including systematic reviews such as https://jamanetwork.com/journals/jama/fullarticle/1679406, which highlights the clinical need for improved therapies in this area. Similarly, research on viral infections in immunocompromised patients, available at https://pubmed.ncbi.nlm.nih.gov/16769842/, underscores the broader medical need for effective antiviral approaches across multiple disease states.

The acquisition positions Okogen to address significant unmet medical needs across multiple therapeutic areas with a single platform technology. By controlling the full intellectual property portfolio for ranpirnase, the company can now pursue coordinated development across ophthalmology, respiratory medicine, dermatology, and biodefense applications. This strategic consolidation of assets under a single development organization could accelerate the translation of ranpirnase from investigational compound to approved therapeutic across multiple indications. The move represents a significant investment in antiviral development at a time when global health systems face increasing threats from both established and emerging viral pathogens. With ranpirnase's established safety profile and novel mechanism of action, Okogen now possesses a platform technology that could potentially address viral infections through a common biological approach rather than pathogen-specific interventions.